After the positive outcome from the ASM, the chances of approval could be anywhere from 50% to 75%, depending on one's perspective. However, I don't want to pump the stock based solely on the meeting. based on yesterday's information, the CHM meeting took place back in June, before the inspections were completed. What if any issues were discovered during those inspections or other evaluations? In my opinion, investing in any clinical-stage biotech stock is inherently risky until approval is granted. For a new investor, relying on the ASM recommendation means you're looking at roughly a 50% chance of approval. Personally, I’m comfortable investing in biotech stocks with a 50% chance of approval, which is why I’d describe it as a bullish move.
Market Data 
Markets 
AI
